Filsuvez
What Filsuvez is used for
Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Filsuvez
- Active substance
- birch bark extract
- Disease area
- Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional
- Medicine group
- Preparations for treatment of wounds and ulcers
- ATC code
- D03AX13
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Filsuvez used for?
Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.
What is the active substance in Filsuvez?
Filsuvez contains birch bark extract.
Who makes Filsuvez?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A.
Is Filsuvez an orphan medicine?
Yes. Filsuvez is designated an orphan medicine in the EU, for a rare disease (Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU